Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

Osteoporosis, fractures, and death in patients with RA using JAK versus TNF inhibitors

Dual effects of JAK vs TNF inhibitors on osteoporosis, fractures and mortality in rheumatoid arthritis: a real-world cohort study.

Frontiers in immunology

Citation & Authors

Front Immunol. 2026;17:1745048.

Chunyan Huang; Daorong Hong; Yao-Min Hung; Shiow-Ing Wang; James Cheng-Chung Wei; Xiaoqing Chen

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

purpose

To compare real-world skeletal and survival outcomes in patients with rheumatoid arthritis (RA) receiving JAK versus TNF inhibitors.

method

This retrospective cohort study used a collaborative electronic health record network covering 2016–2024. After 1:1 propensity score matching, each group included 16,572 patients, followed for up to 5 years. The primary outcomes were the composite of any fracture or osteoporosis, fracture and osteoporosis separately, and all-cause mortality.

result

In the matched cohort, JAK inhibitors were associated with lower risks of the composite outcome (HR 0.930) and osteoporosis (0.906) than TNF inhibitors, but a reduction in fracture risk was not clearly observed. JAK inhibitors were also associated with higher all-cause mortality (1.582). Subgroup estimates suggested possible heterogeneity, but these findings were exploratory.

Conclusion

In this large electronic health record cohort, initiation of JAK inhibitors was associated with fewer osteoporosis-related outcomes but higher all-cause mortality than initiation of TNF inhibitors. Given the observational design, potential residual confounding, and limited follow-up for most patients, the findings should be interpreted as associations and validated in other datasets and prospective studies.

Reasons for research

To compare real-world skeletal outcomes and all-cause mortality associated with JAK versus TNF inhibitor use in patients with RA.

Main results

In the propensity score-matched cohort, JAK inhibitors were associated with fewer osteoporosis-related outcomes but higher all-cause mortality.

meaning

These observational findings suggest a potential trade-off between benefits and risks, highlighting the need for individualized risk–benefit discussions and validation in other datasets and prospective studies.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY ↗;Translations are subject to the same licensing conditions.